We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SOLS:NASDAQSolstice Advanced Materials Inc. Analysis

Data as of 2026-05-25 - not real-time

$81.76

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Solstice Advanced Materials (SOLS) is trading at $81.76, marginally below its 20‑day SMA of 82.20 but above the 50‑day SMA of 79.27, indicating a short‑term pull‑back from recent highs. The stock’s RSI of 50.2 and a bearish MACD histogram (‑0.48) signal weakening momentum, while the 30‑day volatility of 51.5% and a beta of 1.47 underscore heightened market risk. Fundamentally, the company carries an extreme forward PE of 26.1 versus a trailing PE of 68.7, a price‑to‑book ratio of 8.74 and a dividend yield of just 0.37%, suggesting the shares are significantly overvalued and the dividend may not be sustainable given zero free cash flow and a debt‑to‑equity of 165.2. Sector‑wise, the Basic Materials space is cyclical, and with a high regulatory exposure for low‑global‑warming‑potential refrigerants, the combined sector, regulatory and geographic risks are assessed as medium‑high, while the stock’s liquidity appears only moderate.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • bearish MACD histogram indicating negative price momentum
  • current price sitting below the 20‑day SMA, a technical sign of short‑term weakness
  • elevated 30‑day volatility (>50%) amplifying downside risk

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • forward PE of 26.1 aligns with growth expectations
  • revenue growth of 10.6% YoY and stable volume trend
  • support level at $76.03 providing a near‑term floor

Long Term

> 3 years
Neutral
Model confidence: 4/10

Key Factors

  • excessive debt‑to‑equity ratio (165.2) limiting financial flexibility
  • zero free cash flow raises concerns about cash generation sustainability
  • regulatory exposure in specialty chemicals and low‑GWP refrigerants

Key Metrics & Analysis

Financial Health

Revenue Growth10.60%
Profit Margin4.72%
P/E Ratio68.7
ROE10.74%
Debt/Equity165.22
P/B Ratio8.7
Op. Cash Flow$494.0M

Technical Analysis

TrendBullish
RSI50.2
Support$76.03
Resistance$90.80
MA 20$82.20
MA 50$79.27
MA 200$64.37
MACDBearish
VolumeStable
Fear & Greed Index91.7

Valuation

Fair Value$33.01
Target Price$88.17
Upside/Downside7.84%
GradeOvervalued
TypeBlend
Dividend Yield0.37%

Risk Assessment

Beta1.47
Volatility51.48%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.